The Medicines Company (NASDAQ:MDCO) had its price objective lowered by Citigroup Inc. from $45.00 to $44.00 in a report published on Monday. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. ValuEngine cut shares of The Medicines from a sell rating to a strong sell rating in a report on Saturday, May 20th. Cowen and Company boosted their target price on shares of The Medicines from $39.00 to $61.00 and gave the company an outperform rating in a report on Wednesday, April 19th. Oppenheimer Holdings, Inc. started coverage on shares of The Medicines in a report on Monday, May 22nd. They set a market perform rating and a $50.00 target price on the stock. CIBC set a $50.00 price target on shares of The Medicines in a research report on Tuesday, May 23rd. Finally, Jefferies Group LLC restated a buy rating and set a $62.00 price target on shares of The Medicines in a research report on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The Medicines currently has an average rating of Buy and an average price target of $52.00.

Shares of The Medicines (NASDAQ:MDCO) opened at 36.66 on Monday. The company’s 50-day moving average price is $37.87 and its 200-day moving average price is $44.60. The Medicines has a 12 month low of $30.80 and a 12 month high of $55.95. The firm’s market cap is $2.64 billion.

The Medicines (NASDAQ:MDCO) last issued its earnings results on Wednesday, August 9th. The company reported ($5.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.29) by $4.23. The Medicines had a negative net margin of 670.46% and a negative return on equity of 137.20%. The business had revenue of $18.74 million for the quarter, compared to the consensus estimate of $29.64 million. During the same period in the previous year, the firm earned ($0.62) EPS. The company’s revenue was down 65.8% compared to the same quarter last year. On average, analysts predict that The Medicines will post ($7.82) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Citigroup Inc. Cuts The Medicines Company (MDCO) Price Target to $44.00” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/17/citigroup-inc-cuts-the-medicines-company-mdco-price-target-to-44-00.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in MDCO. American Century Companies Inc. raised its position in shares of The Medicines by 4.7% in the first quarter. American Century Companies Inc. now owns 68,597 shares of the company’s stock valued at $3,354,000 after buying an additional 3,063 shares during the period. Advisors Asset Management Inc. raised its position in shares of The Medicines by 72.5% in the first quarter. Advisors Asset Management Inc. now owns 26,217 shares of the company’s stock valued at $1,282,000 after buying an additional 11,018 shares during the period. Tyers Asset Management LLC raised its position in shares of The Medicines by 12.4% in the first quarter. Tyers Asset Management LLC now owns 3,304 shares of the company’s stock valued at $162,000 after buying an additional 364 shares during the period. Great West Life Assurance Co. Can raised its position in shares of The Medicines by 8.7% in the first quarter. Great West Life Assurance Co. Can now owns 101,034 shares of the company’s stock valued at $4,938,000 after buying an additional 8,111 shares during the period. Finally, Whittier Trust Co. raised its position in shares of The Medicines by 5.2% in the first quarter. Whittier Trust Co. now owns 25,034 shares of the company’s stock valued at $1,224,000 after buying an additional 1,232 shares during the period.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Stock Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related stocks with our FREE daily email newsletter.